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Stopping routine vaccination for tuberculosis in
schools
Brings the UK into line with much of the rest of the world
From autumn 2005 the long running routineprogramme to vaccinate schoolchildren againsttuberculosis with BCG vaccine will stop. This fol-
lows a decision by the chief medical, nursing, and
pharmaceutical officers in July that there should be
selective vaccination of high risk infants and other
groups rather than routine vaccination of adolescents
negative on tuberculin testing.1 This decision comes
after several years of discussion within the Joint Com-
mittee on Vaccination and Immunisation, and it closes
an important chapter in the complex history of BCG
vaccination. It comes as notifications of tuberculosis in
England and Wales are at their highest level since
1983. The decision is well justified.
This BCG programme has been unique from its
start in the mid-1950s, when a Danish vaccine (later
produced by Glaxo) was introduced on the basis of
efficacy shown in a trial carried out by the UK Medical
Research Council.2 The trial had been carried out in
approximately 30 000 adolescents for pragmatic
reasons—in order to recruit participants who were still
tuberculin negative, but who were about to enter a
period of high risk of disease. That trial remains the
most rigorous trial of BCG vaccination carried out
anywhere and is an important monument in the
history of research in tuberculosis.
At the same time trials were carried out by the US
Public Health Service (USPHS) in Georgia, Alabama,
and Puerto Rico which found that the Tice BCG
vaccines used there had little or no effect.3 Faced with
these results, each nation did the locally responsible
thing—the USPHS decided not to introduce BCG vac-
cination because they had no evidence that it worked
among their populations, whereas the UK authorities
did introduce it, as they had good evidence of its value.
This touched off a controversy over the magnitude
and determinants of the efficacy of BCG, which still
continues. Many explanations have been proposed.
Perhaps the most popular is that different populations
are exposed to different environmental mycobacteria,
which can provide as much immunity as BCG or
otherwise interfere with it, and that the US trials
happen to have been conducted in areas where such
environmental exposure is highly prevalent.4 Whatever
the explanation for those initial trial results, they deter-
mined the policy of vaccinating adolescents in the
United Kingdom, and the efficacy of the vaccines so
given has since been confirmed repeatedly in observa-
tional studies.4 5
The epidemiology of tuberculosis in the United
Kingdom has changed greatly over the years since the
BCG programme began. The annual risk of infection
has declined from about 2% a year in 1950 to less than
1 per 1000 today, and the disease has become increas-
ingly restricted to identifiable segments of the popula-
tion, in particular immigrant communities: two thirds
of cases in 2003 were in people born outside the
United Kingdom.6 Recent increases in the incidence of
tuberculosis in the UK thus reflect patterns and trends
in the movements of populations and in the
epidemiology of tuberculosis worldwide.
That non-indigenous groups were at higher risk
was first recognised in the 1960s and led to a national
policy encouraging health authorities to consider sup-
plementary BCG programmes for neonates or for
people in contact with tuberculosis in these communi-
ties. The Joint Committee on Vaccination and
Immunisation repeatedly examined the cost effective-
ness of the routine programme in schools as an
increasing proportion of the population at high risk
received the vaccine in infancy and as the risk of
disease in the general population fell. The number of
cases in people born in the United Kingdom reached
an all time low in 2003.6
Although the criteria set by the International
Union against Tuberculosis and Lung Disease for
moving away from routine BCG vaccination were
achieved in the 1990s,7 policy makers were reluctant to
stop the programme in schools because of lingering
concerns that increases in the prevalence of HIV and
in tuberculosis internationally might increase the risk
of tuberculosis in the UK general population. This has
not occurred, and it is clear that the risk of tuberculosis
among immigrant communities declines over time
once they have settled in the United Kingdom and that
the imported disease has not led to increases in the risk
of disease for the indigenous population.
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Under the new policy, BCG vaccination will be
offered to infants in communities with an average inci-
dence of tuberculosis of at least 40 per 100 000 and to
unvaccinated individuals who come from, or whose
parents or grandparents come from, countries where
the incidence exceeds 40 per 100 000. Most people
born in the United Kingdom will thus probably never
receive BCG vaccination, and most will not be exposed
to mycobacteria. This means that tuberculin testing will
become increasingly efficient as a means of identifying
people exposed to and latently infected with the tuber-
cle bacillus, who may be given prophylaxis.
The change from routine to targeted vaccination is
accompanied by technical changes. The Glaxo BCG
vaccine has been replaced by one from the Danish
Statens Seruminstitut and the multipuncture “Heaf”
technique for tuberculin testing is being replaced by
the intradermal injection “Mantoux” technique, which
is the standard in the rest of the world. All of these
changes bring the UK’s approach to preventing infec-
tion with tuberculosis in line with policies and practice
in many other countries.
BCG vaccination will continue to have an
important role in protecting children in high risk
populations from tuberculosis. Coupled with vigorous
efforts to identify and appropriately treat cases, and to
ascertain and offer prophylaxis to people with latent
infection, the new policy should allow more efficient
control of tuberculosis in the entire UK population.
Paul Fine professor of communicable disease epidemiology
Department of Infectious and Topical Diseases, London School of
Hygiene and Tropical Medicine, London WC1E 7HT
(paul.fine@lshtm.ac.uk)
Competing interests: PF is a member of the BCG Subcommittee
of the Joint Committee on Vaccination and Immunisation and
took part in discussions leading to this policy change.
1 Donaldson L, Beasley C, Smith J. Changes to the BCG vaccination
programme. 6 July 2005. (CMO letter.) www.immunisation.nhs.uk/files/
CMO060705.pdf (accessed 15 Sep 2005).
2 Hart PD’A, Sutherland I. BCG and vole bacillus vaccines in the
prevention of tuberculosis in adolescents and early life. Final report to
the Medical Research Council. BMJ 1977;ii:293-5.
3 Comstock GW, Palmer CE. Long term results of BCG vaccination in the
southern United States. Am Rev Respir Dis 1966;93:171-83.
4 Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. Issues relating to the
use of BCG in immunization programmes: a discussion document.
Geneva: World Health Organization, 1999. www.who.int/
vaccine_research/documents/en/bcg_vaccines.pdf (accessed 15 Sep
2005).
5 Sutherland I, Springett VH. Effectiveness of BCG vaccination in England
and Wales in 1983. Tubercle 1987;68:81-92.
6 Health Protection Agency. Tuberculosis. www.hpa.org.uk/infections/
topics_az/tb/menu.htm (accessed 15 Sep 2005).
7 International Union against Tuberculosis and Lung Disease. Criteria for
discontinuation of vaccination programmes using Bacille Calmette
Guerin (BCG) in countries with a low prevalence of tuberculosis. Tubercle
and Lung Dis 1994;75:179-81.
The Japanese healthcare system
The issue is to solve the “tragedy of the commons” without making another
The Japanese medical insurance system has aunique combination of characteristics that hasled to the overuse of tests and drugs,
unconstrained demand from patients, and an explo-
sion of costs. Unless the system of medical insurance
and reimbursement of healthcare providers changes,
the combination of increasing technological advances,
an ageing population, and unconstrained demand will
produce a crisis in Japanese health care. Japan is only
belatedly waking up to this crisis.
The Japanese medical insurance system has four
characteristics that lie at the root of the problem.
Firstly, Japanese citizens are covered comprehensively
and exclusively by either national medical insurance
(for the self employed) or social insurance (for employ-
ees). Beneficiaries have to make some co-payments,
which are capped depending on income.1 Secondly,
mixed private and insurance payments are
prohibited—that is, beneficiaries cannot pay privately
for medical services that are covered by their medical
insurance. Thirdly, beneficiaries have guaranteed
access to any healthcare providers, from general prac-
titioners to specialists, without being charged a
premium fee. Finally, healthcare providers and institu-
tions are reimbursed through fees for service.
Fuelled by economic growth after the second world
war and facilitated by the healthcare system, Japan has
become one of the most medically advanced nations in
the world, especially in its service quantity. Compared
with other developed countries in the Organisation for
Economic Cooperation and Development (OECD),
Japan is the runaway leader in the number of magnetic
resonance imaging and computed tomography scan-
ners per head of population.2 Because they are paid for
each prescription or test rather than time spent with
patients, healthcare providers, both private and public,
are driven to prescribe more drugs and to order more
imaging and tests.
Japanese patients visit outpatient clinics more often
and stay in hospitals longer than patients in other
OECD countries.2 Profits gained from a “three-hour
wait, three-minute contact” consultation (with an
emphasis on ordering tests and prescribing drugs
during the three minutes) primarily benefit pharma-
ceutical and medical equipment companies. Health-
care expenditures, both per head and as a percentage
of gross domestic product, continue to increase despite
the economic growth rate remaining low throughout
the past 10 years. In Japan’s ageing society, the
economic burden rests with the insurers, who
ultimately raise their funds from the working
population and their employers.
Japanese health care is therefore a typical case of
the “tragedy of the commons.”3 The name relates to
grazing land: free access to common grazing land
drives each herdsman to maximise his own take from
the commons, even when it becomes overcrowded with
grazing animals. Ultimately this behaviour ruins the
common land, as well as those who depend on it for
survival. In the Japanese system patients are the herds-
men, and specialists, medical resources, and health
insurance coverage comprise the commons. A more
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